Thomas Jefferson University

Matthias Schnell

TitleProfessor & Chair JMC, gfd
InstitutionThomas Jefferson University
DepartmentChairman - JMC - Thomas Jefferson University
Address951 Locust Street
Philadelphia PA 19107
Phone2155034634
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R21AI044340     (SCHNELL, MATTHIAS JOHANNES)Sep 30, 1998 - Sep 29, 2000
    NIH
    RABIES VIRUS BASED VECTORS AS AN HIV1 VACCINE
    Role: Principal Investigator
    R21AI049153     (SCHNELL, MATTHIAS JOHANNES)Mar 15, 2001 - May 31, 2005
    NIH
    Rabies Virus-Based Vectors as an HIV -1 Vaccine
    Role: Principal Investigator
    R01AI049153     (SCHNELL, MATTHIAS JOHANNES)Mar 15, 2001 - Feb 28, 2010
    NIH
    Rabies Virus-Based Vectors as an HIV-1 Vaccine
    Role: Principal Investigator
    R21AI051170     (SCHNELL, MATTHIAS JOHANNES)Jul 1, 2002 - Jun 30, 2005
    NIH
    Prime/Boost Immunization against HIV-1 by Viral Vectors
    Role: Principal Investigator
    R21AI062807     (SCHNELL, MATTHIAS JOHANNES)Jul 5, 2005 - Jun 30, 2008
    NIH
    Killed Rhabdoviruses as Novel Anthrax Vaccines
    Role: Principal Investigator
    R01MH074375     (SCHNELL, MATTHIAS JOHANNES)Sep 15, 2005 - Aug 31, 2009
    NIH
    Astrocytes and Restricted HIV-1 Replication
    Role: Principal Investigator
    R41AI063822     (SCHNELL, MATTHIAS JOHANNES)Apr 15, 2006 - Mar 31, 2009
    NIH
    A novel rhabdovirus-based anthrax vaccine
    Role: Principal Investigator
    R41AI073064     (SCHNELL, MATTHIAS JOHANNES)Apr 1, 2008 - Sep 30, 2010
    NIH
    A novel vaccine: botulinum neurotoxin subunit on a viral carrier.
    Role: Principal Investigator
    R21AI081388     (SCHNELL, MATTHIAS JOHANNES)Jun 1, 2009 - May 31, 2012
    NIH
    Bat rabies virus in its natural host
    Role: Principal Investigator
    P01AI082325     (SCHNELL, MATTHIAS JOHANNES)Sep 1, 2009 - Aug 31, 2012
    NIH
    Functional Analysis of NSV-based HIV vectors
    Role: Principal Investigator
    R21NS074006     (SCHNELL, MATTHIAS JOHANNES)Jul 1, 2011 - Jun 30, 2015
    NIH
    Fate of neurons following immune-mediated viral clearance
    Role: Principal Investigator
    R42AI073064     (SCHNELL, MATTHIAS JOHANNES)Jun 21, 2012 - May 31, 2016
    NIH
    A novel vaccine: botulinum neurotoxin subunit on a viral carrier.
    Role: Principal Investigator
    R01AI105204     (SCHNELL, MATTHIAS JOHANNES)Feb 1, 2013 - Jan 31, 2020
    NIH
    Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine
    Role: Principal Investigator
    R01AI127823     (SCHNELL, MATTHIAS JOHANNES)Nov 15, 2016 - Oct 31, 2020
    NIH
    Drug discovery against lyssaviruses by high thoughput screening
    Role: Principal Investigator
    R01AI123272     (SCHNELL, MATTHIAS JOHANNES)Nov 22, 2016 - Oct 31, 2021
    NIH
    Development of a single-dose rabies virus vaccine
    Role: Principal Investigator
    R21AI128175     (SCHNELL, MATTHIAS JOHANNES)Dec 1, 2016 - Nov 30, 2019
    NIH
    Toward an Pan-lyssavirus vaccine
    Role: Principal Investigator
    R21AI135361     (SCHNELL, MATTHIAS JOHANNES)May 16, 2018 - Apr 30, 2021
    NIH
    Development of Rabies-based Virus-like Particles
    Role: Principal Investigator
    T32AI134646     (SCHNELL, MATTHIAS JOHANNES;SIGAL, LUIS J)Sep 1, 2018 - Aug 31, 2023
    NIH
    Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer
    Role: Co-Principal Investigator
    R01AI149795     (SCHNELL, MATTHIAS JOHANNES)Jan 1, 2020 - Dec 31, 2025
    NIH
    Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses
    Role: Principal Investigator
    R21AI158044     (SCHNELL, MATTHIAS JOHANNES)Jul 16, 2020 - Jun 30, 2022
    NIH
    Toward a protective Covid-19 vaccine utilizing an established vector platform
    Role: Principal Investigator
    R01AI154542     (PAL, UTPAL)Jul 20, 2020 - Jun 30, 2026
    NIH
    Multivalent Tick-Microbe targeted Lyme disease vaccines
    Role: Co-Principal Investigator
    R01AI167295     (SCHNELL, MATTHIAS JOHANNES)Aug 25, 2022 - Jul 31, 2026
    NIH
    Analysis of a novel Crimean-Congo hemorrhagic fever vaccine and its mechanism of protection in rodent models
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Scher G, Yankowski C, Kurup D, Josleyn NM, Wilkinson ER, Wells J, Steffens J, Lynn G, Vantongeren S, Zeng X, Twenhafel N, Cashman KA, Schnell MJ. Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease. NPJ Vaccines. 2024 Aug 09; 9(1):143. PMID: 39122759.
      Citations:    
    2. Ben Hamed S, Myers JF, Chandwani A, Wirblich C, Kurup D, Paran N, Schnell MJ. Toward the Development of a Pan-Lyssavirus Vaccine. Viruses. 2024 Jul 10; 16(7). PMID: 39066269.
      Citations:    
    3. Rios S, Bhattachan B, Vavilikolanu K, Kitsou C, Pal U, Schnell MJ. The Development of a Rabies Virus-Vectored Vaccine against Borrelia burgdorferi, Targeting BBI39. Vaccines (Basel). 2024 Jan 12; 12(1). PMID: 38250891.
      Citations:    
    4. Scher G, Bente DA, Mears MC, Cajimat MNB, Schnell MJ. GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus. NPJ Vaccines. 2023 May 20; 8(1):73. PMID: 37210392.
      Citations:    
    5. Yankowski C, Kurup D, Wirblich C, Schnell MJ. Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge. NPJ Vaccines. 2023 Feb 08; 8(1):10. PMID: 36754965.
      Citations:    
    6. Yankowski C, Wirblich C, Kurup D, Schnell MJ. Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity. NPJ Vaccines. 2022 Sep 23; 7(1):110. PMID: 36151100.
      Citations:    
    7. Kurup D, Wirblich C, Zabihi Diba L, Lambert R, Watson M, Shaikh N, Ramage H, Solomides C, Schnell MJ. A Single Dose of the Deactivated Rabies-Virus Vectored COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. Viruses. 2022 May 24; 14(6). PMID: 35746597.
      Citations:    
    8. Kurup D, Myers J, Schnell MJ. Current vaccine strategies against SARS-CoV-2: Promises and challenges. J Allergy Clin Immunol. 2022 May 23. PMID: 35618046.
      Citations:    
    9. Kurup D, Wirblich C, Lambert R, Diba LZ, Leiby BE, Schnell MJ. Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract. NPJ Vaccines. 2022 Apr 19; 7(1):43. PMID: 35440656.
      Citations:    
    10. Puligedda RD, Al-Saleem FH, Wirblich C, Kattala CD, Jovic M, Geiszler L, Devabhaktuni H, Feuerstein GZ, Schnell MJ, Sack M, Livornese LL, Dessain SK. A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue. Diagnostics (Basel). 2021 Nov 12; 11(11). PMID: 34829439.
      Citations:    
    11. Lee JWL, Tikhonov DS, Chopra P, Maclot S, Steber AL, Gruet S, Allum F, Boll R, Cheng X, D?sterer S, Erk B, Garg D, He L, Heathcote D, Johny M, Kazemi MM, K?ckert H, Lahl J, Lemmens AK, Loru D, Mason R, M?ller E, Mullins T, Olshin P, Passow C, Peschel J, Ramm D, Rompotis D, Schirmel N, Trippel S, Wiese J, Ziaee F, Bari S, Burt M, K?pper J, Rijs AM, Rolles D, Techert S, Eng-Johnsson P, Brouard M, Vallance C, Manschwetus B, Schnell M. Time-resolved relaxation and fragmentation of polycyclic aromatic hydrocarbons investigated in the ultrafast XUV-IR regime. Nat Commun. 2021 Oct 20; 12(1):6107. PMID: 34671016.
      Citations:    
    12. Malherbe DC, Kurup D, Wirblich C, Ronk AJ, Mire C, Kuzmina N, Shaik N, Periasamy S, Hyde MA, Williams JM, Shi PY, Schnell MJ, Bukreyev A. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. NPJ Vaccines. 2021 Jul 22; 6(1):91. PMID: 34294728.
      Citations:    
    13. Kurup D, Schnell MJ. SARS-CoV-2 vaccines - the biggest medical research project of the 21st century. Curr Opin Virol. 2021 08; 49:52-57. PMID: 34049261.
      Citations:    
    14. Kurup D, Malherbe DC, Wirblich C, Lambert R, Ronk AJ, Zabihi Diba L, Bukreyev A, Schnell MJ. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLoS Pathog. 2021 03; 17(3):e1009383. PMID: 33765062.
      Citations:    
    15. Kurup D, Fisher CR, Scher G, Yankowski C, Testa A, Keshwara R, Abreu-Mota T, Lambert R, Ferguson M, Rinaldi W, Ruiz L, Wirblich C, Schnell MJ. Tetravalent rabies-vectored Filovirus and Lassa fever vaccine induces long-term immunity in nonhuman primates. J Infect Dis. 2021 Jan 09. PMID: 33421072.
      Citations:    
    16. Scher G, Schnell MJ. Rhabdoviruses as vectors for vaccines and therapeutics. Curr Opin Virol. 2020 Oct; 44:169-182. PMID: 33130500.
      Citations:    
    17. Kurup D, Wirblich C, Ramage H, Schnell MJ. Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2. NPJ Vaccines. 2020; 5:98. PMID: 33088593.
      Citations:    
    18. Fisher CR, Lowe DE, Smith TG, Yang Y, Hutson CL, Wirblich C, Cingolani G, Schnell MJ. Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups. Cell Rep. 2020 Jul 21; 32(3):107920. PMID: 32697993.
      Citations:    
    19. Du Pont V, Wirblich C, Yoon JJ, Cox RM, Schnell MJ, Plemper RK. Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor. J Virol. 2020 Apr 22. PMID: 32321812.
      Citations:    
    20. Kurup D, Fisher CR, Smith TG, Abreu-Mota T, Yang Y, Jackson FR, Gallardo-Romero N, Franka R, Bronshtein V, Schnell MJ. Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge. J Infect Dis. 2019 Aug 03. PMID: 31374568.
      Citations:    
    21. Keshwara R, Shiels T, Postnikova E, Kurup D, Wirblich C, Johnson RF, Schnell MJ. Erratum: Publisher Correction: Rabies-based vaccine induces potent immune responses against Nipah virus. NPJ Vaccines. 2019; 4:18. PMID: 31098303.
      Citations:    
    22. Keshwara R, Shiels T, Postnikova E, Kurup D, Wirblich C, Johnson RF, Schnell MJ. Rabies-based vaccine induces potent immune responses against Nipah virus. NPJ Vaccines. 2019; 4:15. PMID: 31016033.
      Citations:    
    23. Taylor E, Banyard AC, Bourhy H, Cliquet F, Ertl H, Fehlner-Gardiner C, Horton DL, Mani RS, Müller T, Rupprecht CE, Schnell MJ, Del Rio Vilas V, Fooks AR. Avoiding preventable deaths: The scourge of counterfeit rabies vaccines. Vaccine. 2019 Mar 25. PMID: 30922698.
      Citations:    
    24. Qin S, Volokhov D, Rodionova E, Wirblich C, Schnell MJ, Chizhikov V, Dabrazhynetskaya A. A new recombinant rabies virus expressing a green fluorescent protein: A novel and fast approach to quantify virus neutralizing antibodies. Biologicals. 2019 Mar 18. PMID: 30898479.
      Citations:    
    25. Du Pont V, Plemper RK, Schnell MJ. Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Curr Opin Virol. 2019 Feb 09; 35:1-13. PMID: 30753961.
      Citations:    
    26. Keshwara R, Hagen KR, Abreu-Mota T, Papaneri AB, Liu D, Wirblich C, Johnson RF, Schnell MJ. A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein is Dependent Upon ADCC for Protection Against Marburg Virus Disease in a Murine Model. J Virol. 2018 Dec 19. PMID: 30567978.
      Citations:    
    27. Liu DX, Perry DL, Evans DeWald L, Cai Y, Hagen KR, Cooper TK, Huzella LM, Hart R, Bonilla A, Bernbaum JG, Janosko KB, Adams R, Johnson RF, Kuhn JH, Schnell MJ, Crozier I, Jahrling PB, de la Torre JC. Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus). J Infect Dis. 2018 Dec 05. PMID: 30517671.
      Citations:    
    28. Abreu-Mota T, Hagen KR, Cooper K, Jahrling PB, Tan G, Wirblich C, Johnson RF, Schnell MJ. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat Commun. 2018 Oct 11; 9(1):4223. PMID: 30310067.
      Citations:    
    29. Fisher CR, Schnell MJ. New developments in rabies vaccination. Rev Sci Tech. 2018 Aug; 37(2):657-672. PMID: 30747119.
      Citations:    
    30. MacGibeny MA, Koyuncu OO, Wirblich C, Schnell MJ, Enquist LW. Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons. PLoS Pathog. 2018 Jul; 14(7):e1007188. PMID: 30028873.
      Citations:    
    31. Fisher CR, Streicker DG, Schnell MJ. The spread and evolution of rabies virus: conquering new frontiers. Nat Rev Microbiol. 2018 Apr; 16(4):241-255. PMID: 29479072.
      Citations:    
    32. Perry DL, Huzella LM, Bernbaum JG, Holbrook MR, Jahrling PB, Hagen KR, Schnell MJ, Johnson RF. Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease. Am J Pathol. 2018 Mar; 188(3):550-558. PMID: 29429544.
      Citations:    
    33. Davis BM, Fensterl V, Lawrence TM, Hudacek AW, Sen GC, Schnell MJ. Ifit2 is a Restriction Factor in Rabies Virus Pathogenicity. J Virol. 2017 Jun 21. PMID: 28637751.
      Citations:    
    34. Schnell MJ. Progress in Ebola Virus Vaccine Development. J Infect Dis. 2017 Jun 15; 215(12):1775-1776. PMID: 28431160.
      Citations:    
    35. da Fontoura Budaszewski R, Hudacek A, Sawatsky B, Krämer B, Yin X, Schnell MJ, von Messling V. Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens. J Virol. 2017 Apr 15; 91(8). PMID: 28148801.
      Citations:    
    36. Walsh PD, Kurup D, Hasselschwert DL, Wirblich C, Goetzmann JE, Schnell MJ. The Final (Oral Ebola) Vaccine Trial on Captive Chimpanzees? Sci Rep. 2017 Mar 09; 7:43339. PMID: 28277549.
      Citations:    
    37. Miller KD, Schnell MJ, Rall GF. Keeping it in check: chronic viral infection and antiviral immunity in the brain. Nat Rev Neurosci. 2016 Dec; 17(12):766-776. PMID: 27811921.
      Citations:    
    38. Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ. One-Health: A Safe, Efficient Dual-use Vaccine for Humans and Animals against MERS-CoV and Rabies Virus. J Virol. 2016 Nov 2. PMID: 27807241.
      Citations:    
    39. Keshwara R, Johnson RF, Schnell MJ. Toward an Effective Ebola Virus Vaccine. Annu Rev Med. 2017 Jan 14; 68:371-386. PMID: 27686015.
      Citations:    
    40. Johnson RF, Kurup D, Hagen KR, Fisher C, Keshwara R, Papaneri A, Perry DL, Cooper K, Jahrling PB, Wang JT, Ter Meulen J, Wirblich C, Schnell MJ. An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models. J Infect Dis. 2016 Oct 15; 214(suppl 3):S342-S354. PMID: 27456709.
      Citations:    
    41. Khanikaev AB, Arju N, Fan Z, Purtseladze D, Lu F, Lee J, Sarriugarte P, Schnell M, Hillenbrand R, Belkin MA, Shvets G. Experimental demonstration of the microscopic origin of circular dichroism in two-dimensional metamaterials. Nat Commun. 2016 06 22; 7:12045. PMID: 27329108.
      Citations:    
    42. Reardon TR, Murray AJ, Turi GF, Wirblich C, Croce KR, Schnell MJ, Jessell TM, Losonczy A. Rabies Virus CVS-N2c(?G) Strain Enhances Retrograde Synaptic Transfer and Neuronal Viability. Neuron. 2016 Feb 17; 89(4):711-24. PMID: 26804990.
      Citations:    
    43. Davis BM, Rall GF, Schnell MJ. Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask). Annu Rev Virol. 2015 Nov; 2(1):451-71. PMID: 26958924.
      Citations:    
    44. Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney JE, Johnson RF, Schnell MJ. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. J Infect Dis. 2015 Oct 1; 212 Suppl 2:S414-24. PMID: 26063224.
      Citations:    
    45. Pfaller CK, Cattaneo R, Schnell MJ. Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology. 2015 May; 479-480:331-44. PMID: 25702088.
      Citations:    
    46. Papaneri AB, Bernbaum JG, Blaney JE, Jahrling PB, Schnell MJ, Johnson RF. Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine. Virus Res. 2015 Feb 2; 197:54-8. PMID: 25481284.
      Citations:    
    47. Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell MJ. Rhabdovirus-Based Vaccine Platforms against Henipaviruses. J Virol. 2015 Jan 1; 89(1):144-54. PMID: 25320306.
      Citations:    
    48. Hudacek AW, Al-Saleem FH, Willet M, Eisemann T, Mattis JA, Simpson LL, Schnell MJ. Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo. Mol Ther Methods Clin Dev. 2014; 1:14046. PMID: 26015984.
      Citations:    
    49. Han Z, Lu J, Liu Y, Davis B, Lee MS, Olson MA, Ruthel G, Freedman BD, Schnell MJ, Wrobel JE, Reitz AB, Harty RN. Small-Molecule Probes Targeting the Viral PPxY-Host Nedd4 Interface Block Egress of a Broad Range of RNA Viruses. J Virol. 2014 Jul 1; 88(13):7294-306. PMID: 24741084.
      Citations:    
    50. Schnell M, Carney PS, Hillenbrand R. Synthetic optical holography for rapid nanoimaging. Nat Commun. 2014 Mar 20; 5:3499. PMID: 24651276.
      Citations:    
    51. McGettigan JP, David F, Figueiredo MD, Minke J, Mebatsion T, Schnell MJ. Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs. Vaccine. 2014 Mar 26; 32(15):1716-9. PMID: 24508037.
      Citations:    
    52. Papaneri AB, Wirblich C, Marissen WE, Schnell MJ. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: Implication for post-exposure treatment. Vaccine. 2013 Dec 2; 31(49):5897-902. PMID: 24120673.
      Citations:    
    53. Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, García-Sastre A, Lyles DS, McGettigan JP, Schnell MJ. Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. PLoS One. 2013; 8(6):e67123. PMID: 23840600.
      Citations:    
    54. Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ. Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 2013 May; 9(5):e1003389. PMID: 23737747.
      Citations:    
    55. Lawrence TM, Hudacek AW, de Zoete MR, Flavell RA, Schnell MJ. Rabies Virus Is Recognized by the NLRP3 Inflammasome and Activates Interleukin-1ß Release in Murine Dendritic Cells. J Virol. 2013 May; 87(10):5848-57. PMID: 23487464.
      Citations:    
    56. Marston DA, McElhinney LM, Banyard AC, Horton DL, Núñez A, Koser ML, Schnell MJ, Fooks AR. Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein. J Gen Virol. 2013 Feb; 94(Pt 2):284-92. PMID: 23100360.
      Citations:    
    57. Gomme EA, Wirblich C, Addya S, Rall GF, Schnell MJ. Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression. PLoS Pathog. 2012 Oct; 8(10):e1002971. PMID: 23071441.
      Citations:    
    58. Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology. 2012 Dec 5; 434(1):18-26. PMID: 22889613.
      Citations:    
    59. Papaneri AB, Wirblich C, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine. 2012 Sep 21; 30(43):6136-41. PMID: 22884661.
      Citations:    
    60. Nguyen TD, Wirblich C, Aizenman E, Schnell MJ, Strick PL, Kandler K. Targeted single-neuron infection with rabies virus for transneuronal multisynaptic tracing. J Neurosci Methods. 2012 Aug 15; 209(2):367-70. PMID: 22749814.
      Citations:    
    61. Nunnari G, Coco C, Pinzone MR, Pavone P, Berretta M, Di Rosa M, Schnell M, Calabrese G, Cacopardo B. The role of micronutrients in the diet of HIV-1-infected individuals. Front Biosci (Elite Ed). 2012; 4:2442-56. PMID: 22652651.
      Citations:    
    62. Alonso-Gonz?lez P, Albella P, Schnell M, Chen J, Huth F, Garc?a-Etxarri A, Casanova F, Golmar F, Arzubiaga L, Hueso LE, Aizpurua J, Hillenbrand R. Resolving the electromagnetic mechanism of surface-enhanced light scattering at single hot spots. Nat Commun. 2012 Feb 21; 3:684. PMID: 22353715.
      Citations:    
    63. Wanjalla CN, Goldstein EF, Wirblich C, Schnell MJ. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus. Virology. 2012 May 10; 426(2):120-33. PMID: 22341782.
      Citations:    
    64. Liang Z, Diamond M, Smith JA, Schnell M, Daniel R. Proliferating cell nuclear antigen is required for loading of the SMCX/KMD5C histone demethylase onto chromatin. Epigenetics Chromatin. 2011; 4(1):18. PMID: 21996408.
      Citations:    
    65. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011 Oct; 85(20):10605-16. PMID: 21849459.
      Citations:    
    66. Nunnari G, Schnell MJ. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection. Front Biosci (Schol Ed). 2011; 3:1032-7. PMID: 21622252.
      Citations:    
    67. Mustafa W, Al-Saleem FH, Nasser Z, Olson RM, Mattis JA, Simpson LL, Schnell MJ. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine. 2011 Jun 20; 29(28):4638-45. PMID: 21549784.
      Citations:    
    68. Gomme EA, Wanjalla CN, Wirblich C, Schnell MJ. Rabies virus as a research tool and viral vaccine vector. Adv Virus Res. 2011; 79:139-64. PMID: 21601047.
      Citations:    
    69. Wirblich C, Schnell MJ. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. J Virol. 2011 Jan; 85(2):697-704. PMID: 21068252.
      Citations:    
    70. Wanjalla CN, Faul EJ, Gomme EA, Schnell MJ. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine. 2010 Dec 10; 29(1):130-40. PMID: 20728525.
      Citations:    
    71. Faul EJ, Wanjalla CN, Suthar MS, Gale M, Wirblich C, Schnell MJ. Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling. PLoS Pathog. 2010; 6(7):e1001016. PMID: 20661430.
      Citations:    
    72. Langley WA, Bradley KC, Li ZN, Smith ME, Schnell MJ, Steinhauer DA. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. J Virol. 2010 Aug; 84(16):8300-7. PMID: 20504926.
      Citations:    
    73. Préhaud C, Wolff N, Terrien E, Lafage M, Mégret F, Babault N, Cordier F, Tan GS, Maitrepierre E, Ménager P, Chopy D, Hoos S, England P, Delepierre M, Schnell MJ, Buc H, Lafon M. Attenuation of rabies virulence: takeover by the cytoplasmic domain of its envelope protein. Sci Signal. 2010; 3(105):ra5. PMID: 20086240.
      Citations:    
    74. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ. Characterization of a single-cycle rabies virus-based vaccine vector. J Virol. 2010 Mar; 84(6):2820-31. PMID: 20053743.
      Citations:    
    75. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol. 2010 Jan; 8(1):51-61. PMID: 19946287.
      Citations:    
    76. Bruhns H, Kreckel H, Miller K, Lestinsky M, Seredyuk B, Mitthumsiri W, Schmitt BL, Schnell M, Urbain X, Rappaport ML, Havener CC, Savin DW. A novel merged beams apparatus to study anion-neutral reactions. Rev Sci Instrum. 2010 Jan; 81(1):013112. PMID: 20113086.
      Citations:    
    77. Mareeva T, Wanjalla C, Schnell MJ, Sykulev Y. A novel composite immunotoxin that suppresses rabies virus production by the infected cells. J Immunol Methods. 2010 Feb 28; 353(1-2):78-86. PMID: 19932697.
      Citations:    
    78. Faul EJ, Lyles DS, Schnell MJ. Interferon response and viral evasion by members of the family rhabdoviridae. Viruses. 2009 Dec; 1(3):832-51. PMID: 21994572.
      Citations:    
    79. Faul EJ, Aye PP, Papaneri AB, Pahar B, McGettigan JP, Schiro F, Chervoneva I, Montefiori DC, Lackner AA, Schnell MJ. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine. 2009 Dec 11; 28(2):299-308. PMID: 19879223.
      Citations:    
    80. Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis. 2009 Oct 15; 200(8):1251-60. PMID: 19764884.
      Citations:    
    81. Preuss MA, Faber ML, Tan GS, Bette M, Dietzschold B, Weihe E, Schnell MJ. Intravenous inoculation of a bat-associated rabies virus causes lethal encephalopathy in mice through invasion of the brain via neurosecretory hypothalamic fibers. PLoS Pathog. 2009 Jun; 5(6):e1000485. PMID: 19543379.
      Citations:    
    82. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009 Apr 15; 69(8):3537-44. PMID: 19351847.
      Citations:    
    83. Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology. 2008 Dec 20; 382(2):226-38. PMID: 18945463.
      Citations:    
    84. Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, McGettigan JP. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine. 2008 Nov 25; 26(50):6405-14. PMID: 18804506.
      Citations:    
    85. Dietzschold B, Li J, Faber M, Schnell M. Concepts in the pathogenesis of rabies. Future Virol. 2008 Sep; 3(5):481-490. PMID: 19578477.
      Citations:    
    86. Wirblich C, Tan GS, Papaneri A, Godlewski PJ, Orenstein JM, Harty RN, Schnell MJ. PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity. J Virol. 2008 Oct; 82(19):9730-8. PMID: 18667490.
      Citations:    
    87. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008 Jul 2; 100(13):950-61. PMID: 18577748.
      Citations:    
    88. Weihe E, Bette M, Preuss MA, Faber M, Sch?fer MK, Rehnelt J, Schnell MJ, Dietzschold B. Role of virus-induced neuropeptides in the brain in the pathogenesis of rabies. Dev Biol (Basel). 2008; 131:73-81. PMID: 18634468.
      Citations:    
    89. Pulmanausahakul R, Li J, Schnell MJ, Dietzschold B. The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. J Virol. 2008 Mar; 82(5):2330-8. PMID: 18094173.
      Citations:    
    90. Li J, McGettigan JP, Faber M, Schnell MJ, Dietzschold B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway. Vaccine. 2008 Jan 17; 26(3):419-26. PMID: 18082293.
      Citations:    
    91. Faber M, Faber ML, Li J, Preuss MA, Schnell MJ, Dietzschold B. Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. J Virol. 2007 Jul; 81(13):7041-7. PMID: 17459937.
      Citations:    
    92. Tan GS, Preuss MA, Williams JC, Schnell MJ. The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription. Proc Natl Acad Sci U S A. 2007 Apr 24; 104(17):7229-34. PMID: 17438267.
      Citations:    
    93. McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis. 2007 Apr 1; 195(7):980-8. PMID: 17330788.
      Citations:    
    94. Tang J, Murtadha M, Schnell M, Eisenlohr LC, Hooper J, Flomenberg P. Human T-cell responses to vaccinia virus envelope proteins. J Virol. 2006 Oct; 80(20):10010-20. PMID: 17005679.
      Citations:    
    95. Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ, Dietzschold B. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology. 2006 Dec 5-20; 356(1-2):147-54. PMID: 16938327.
      Citations:    
    96. Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology. 2006 Sep 30; 353(2):344-56. PMID: 16820183.
      Citations:    
    97. Plesa G, McKenna PM, Schnell MJ, Eisenlohr LC. Immunogenicity of cytopathic and noncytopathic viral vectors. J Virol. 2006 Jul; 80(13):6259-66. PMID: 16775313.
      Citations:    
    98. Tang J, Olive M, Pulmanausahakul R, Schnell M, Flomenberg N, Eisenlohr L, Flomenberg P. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology. 2006 Jul 5; 350(2):312-22. PMID: 16499941.
      Citations:    
    99. Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology. 2006 May 10; 348(2):489-97. PMID: 16480752.
      Citations:    
    100. Faber M, Bette M, Preuss MA, Pulmanausahakul R, Rehnelt J, Schnell MJ, Dietzschold B, Weihe E. Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. J Virol. 2005 Dec; 79(24):15405-16. PMID: 16306612.
      Citations:    
    101. Faber M, Faber ML, Papaneri A, Bette M, Weihe E, Dietzschold B, Schnell MJ. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol. 2005 Nov; 79(22):14141-8. PMID: 16254349.
      Citations:    
    102. McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology. 2006 Jan 20; 344(2):363-77. PMID: 16226782.
      Citations:    
    103. Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, Dietzschold B, Schnell MJ. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol. 2005 May; 86(Pt 5):1435-40. PMID: 15831955.
      Citations:    
    104. Schnell MJ, Tan GS, Dietzschold B. The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. J Neurovirol. 2005 Feb; 11(1):76-81. PMID: 15804964.
      Citations:    
    105. Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology. 2005 Jan 5; 331(1):82-93. PMID: 15582655.
      Citations:    
    106. Dietzschold B, Schnell M, Koprowski H. Pathogenesis of rabies. Curr Top Microbiol Immunol. 2005; 292:45-56. PMID: 15981467.
      Citations:    
    107. Dietzschold ML, Faber M, Mattis JA, Pak KY, Schnell MJ, Dietzschold B. In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. Vaccine. 2004 Dec 9; 23(4):518-24. PMID: 15530701.
      Citations:    
    108. McKenna PM, Aye PP, Dietzschold B, Montefiori DC, Martin LN, Marx PA, Pomerantz RJ, Lackner A, Schnell MJ. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J Virol. 2004 Dec; 78(24):13455-9. PMID: 15564456.
      Citations:    
    109. Faber M, Pulmanausahakul R, Nagao K, Prosniak M, Rice AB, Koprowski H, Schnell MJ, Dietzschold B. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc Natl Acad Sci U S A. 2004 Nov 16; 101(46):16328-32. PMID: 15520387.
      Citations:    
    110. Koser ML, McGettigan JP, Tan GS, Smith ME, Koprowski H, Dietzschold B, Schnell MJ. Rabies virus nucleoprotein as a carrier for foreign antigens. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9405-10. PMID: 15197258.
      Citations:    
    111. Goodrich A, Parveen Z, Dornburg R, Schnell MJ, Pomerantz RJ. Spliced spleen necrosis virus vector RNA is not encapsidated: implications for retroviral replication and vector design. Mol Ther. 2004 Apr; 9(4):557-65. PMID: 15093186.
      Citations:    
    112. Irie T, Licata JM, McGettigan JP, Schnell MJ, Harty RN. Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A. J Virol. 2004 Mar; 78(6):2657-65. PMID: 14990685.
      Citations:    
    113. McKenna PM, Pomerantz RJ, Dietzschold B, McGettigan JP, Schnell MJ. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J Virol. 2003 Dec; 77(23):12782-94. PMID: 14610200.
      Citations:    
    114. McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, Schnell MJ. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol. 2003 Oct; 77(20):10889-99. PMID: 14512539.
      Citations:    
    115. Parveen Z, Mukhtar M, Rafi M, Wenger DA, Siddiqui KM, Siler CA, Dietzschold B, Pomerantz RJ, Schnell MJ, Dornburg R. Cell-type-specific gene delivery into neuronal cells in vitro and in vivo. Virology. 2003 Sep 15; 314(1):74-83. PMID: 14517061.
      Citations:    
    116. Dietzschold B, Faber M, Schnell MJ. New approaches to the prevention and eradication of rabies. Expert Rev Vaccines. 2003 Jun; 2(3):399-406. PMID: 12903805.
      Citations:    
    117. McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res. 2003 Apr; 1(2):229-37. PMID: 15043205.
      Citations:    
    118. McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol. 2003 Jan; 77(1):237-44. PMID: 12477829.
      Citations:    
    119. McGettigan JP, McKenna PM, Schnell MJ. HIV-1 vaccines: the search continues. Clin Lab Med. 2002 Sep; 22(3):799-820, viii. PMID: 12244598.
      Citations:    
    120. Wu X, Gong X, Foley HD, Schnell MJ, Fu ZF. Both viral transcription and replication are reduced when the rabies virus nucleoprotein is not phosphorylated. J Virol. 2002 May; 76(9):4153-61. PMID: 11932380.
      Citations:    
    121. Dietzschold B, Schnell MJ. New approaches to the development of live attenuated rabies vaccines. Hybrid Hybridomics. 2002 Apr; 21(2):129-34. PMID: 12031103.
      Citations:    
    122. Faber M, Pulmanausahakul R, Hodawadekar SS, Spitsin S, McGettigan JP, Schnell MJ, Dietzschold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol. 2002 Apr; 76(7):3374-81. PMID: 11884563.
      Citations:    
    123. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology. 2002 Jan 5; 292(1):24-34. PMID: 11878905.
      Citations:    
    124. Foley HD, Otero M, Orenstein JM, Pomerantz RJ, Schnell MJ. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol. 2002 Jan; 76(1):19-31. PMID: 11739668.
      Citations:    
    125. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, Pomerantz RJ. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 2001 Nov 15; 98(10):3006-15. PMID: 11698284.
      Citations:    
    126. Pulmanausahakul R, Faber M, Morimoto K, Spitsin S, Weihe E, Hooper DC, Schnell MJ, Dietzschold B. Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. J Virol. 2001 Nov; 75(22):10800-7. PMID: 11602721.
      Citations:    
    127. Harty RN, Brown ME, McGettigan JP, Wang G, Jayakar HR, Huibregtse JM, Whitt MA, Schnell MJ. Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J Virol. 2001 Nov; 75(22):10623-9. PMID: 11602704.
      Citations:    
    128. Harty RN, Brown ME, Hayes FP, Wright NT, Schnell MJ. Vaccinia virus-free recovery of vesicular stomatitis virus. J Mol Microbiol Biotechnol. 2001 Oct; 3(4):513-7. PMID: 11545270.
      Citations:    
    129. Qui?ones-Kochs MI, Schnell MJ, Buonocore L, Rose JK. Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses. Virology. 2001 Sep 01; 287(2):427-35. PMID: 11531419.
      Citations:    
    130. McGettigan JP, Sarma S, Orenstein JM, Pomerantz RJ, Schnell MJ. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol. 2001 Sep; 75(18):8724-32. PMID: 11507217.
      Citations:    
    131. Schnell MJ. Viral vectors as potential HIV-1 vaccines. FEMS Microbiol Lett. 2001 Jun 25; 200(2):123-9. PMID: 11425463.
      Citations:    
    132. Morimoto K, Schnell MJ, Pulmanausahakul R, McGettigan JP, Foley HD, Faber M, Hooper DC, Dietzschold B. High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods. 2001 Jun 01; 252(1-2):199-206. PMID: 11334980.
      Citations:    
    133. Morimoto K, McGettigan JP, Foley HD, Hooper DC, Dietzschold B, Schnell MJ. Genetic engineering of live rabies vaccines. Vaccine. 2001 May 14; 19(25-26):3543-51. PMID: 11348722.
      Citations:    
    134. McGettigan JP, Foley HD, Belyakov IM, Berzofsky JA, Pomerantz RJ, Schnell MJ. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol. 2001 May; 75(9):4430-4. PMID: 11287595.
      Citations:    
    135. Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci U S A. 2000 Dec 19; 97(26):14680-5. PMID: 11114165.
      Citations:    
    136. Morimoto K, Foley HD, McGettigan JP, Schnell MJ, Dietzschold B. Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J Neurovirol. 2000 Oct; 6(5):373-81. PMID: 11031690.
      Citations:    
    137. Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A. 2000 Mar 28; 97(7):3544-9. PMID: 10706640.
      Citations:    
    138. Paielli DL, Wing MS, Rogulski KR, Gilbert JD, Kolozsvary A, Kim JH, Hughes J, Schnell M, Thompson T, Freytag SO. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther. 2000 Mar; 1(3):263-74. PMID: 10933942.
      Citations:    
    139. Bennett J, Maguire AM, Cideciyan AV, Schnell M, Glover E, Anand V, Aleman TS, Chirmule N, Gupta AR, Huang Y, Gao GP, Nyberg WC, Tazelaar J, Hughes J, Wilson JM, Jacobson SG. Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A. 1999 Aug 17; 96(17):9920-5. PMID: 10449795.
      Citations:    
    140. Kahn JS, Schnell MJ, Buonocore L, Rose JK. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology. 1999 Feb 01; 254(1):81-91. PMID: 9927576.
      Citations:    
    141. Kim SK, Reed DS, Olson S, Schnell MJ, Rose JK, Morton PA, Lefran?ois L. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Proc Natl Acad Sci U S A. 1998 Sep 01; 95(18):10814-9. PMID: 9724787.
      Citations:    
    142. Schnell MJ, Buonocore L, Boritz E, Ghosh HP, Chernish R, Rose JK. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J. 1998 Aug 10; 17(5):1289-96. PMID: 9482726.
      Citations:    
    143. Chenik M, Schnell M, Conzelmann KK, Blondel D. Mapping the interacting domains between the rabies virus polymerase and phosphoprotein. J Virol. 1998 Mar; 72(3):1925-30. PMID: 9499045.
      Citations:    
    144. Schnell MJ, Johnson JE, Buonocore L, Rose JK. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell. 1997 Sep 05; 90(5):849-57. PMID: 9298897.
      Citations:    
    145. Kretzschmar E, Buonocore L, Schnell MJ, Rose JK. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol. 1997 Aug; 71(8):5982-9. PMID: 9223488.
      Citations:    
    146. Johnson JE, Schnell MJ, Buonocore L, Rose JK. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol. 1997 Jul; 71(7):5060-8. PMID: 9188571.
      Citations:    
    147. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11359-65. PMID: 8876140.
      Citations:    
    148. Mebatsion T, Schnell MJ, Cox JH, Finke S, Conzelmann KK. Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci U S A. 1996 Jul 09; 93(14):7310-4. PMID: 8692989.
      Citations:    
    149. Schnell MJ, Buonocore L, Whitt MA, Rose JK. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol. 1996 Apr; 70(4):2318-23. PMID: 8642658.
      Citations:    
    150. Kretzschmar E, Peluso R, Schnell MJ, Whitt MA, Rose JK. Normal replication of vesicular stomatitis virus without C proteins. Virology. 1996 Feb 15; 216(2):309-16. PMID: 8607260.
      Citations:    
    151. Schnell MJ, Conzelmann KK. Polymerase activity of in vitro mutated rabies virus L protein. Virology. 1995 Dec 20; 214(2):522-30. PMID: 8553554.
      Citations:    
    152. Mebatsion T, Schnell MJ, Conzelmann KK. Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles. J Virol. 1995 Mar; 69(3):1444-51. PMID: 7853476.
      Citations:    
    153. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J. 1994 Sep 15; 13(18):4195-203. PMID: 7925265.
      Citations:    
    154. Conzelmann KK, Schnell M. Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. J Virol. 1994 Feb; 68(2):713-9. PMID: 8289375.
      Citations:    
    Schnell's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (404)
    Explore
    _
    Co-Authors (26)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _